Low Disease Activity Predicts Good Response in CAMEO TrialLow Disease Activity Predicts Good Response in CAMEO Trial

Patients with RA who achieve low disease activity or remission after 6 months on etanercept plus methotrexate continue to have stable disease out to 12 and even 24 months on etanercept alone. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news